IL-17 in spondyloarthritis: Is the T-party over?

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Yeremenko, Nataliya ^a   Baeten, Dominique ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; MYELOPEROXIDASE; IL17A PROTEIN, HUMAN;

ANKYLOSING SPONDYLITIS; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; EDITORIAL; GENETIC POLYMORPHISM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; NEUTROPHIL; PATHOGENESIS; T LYMPHOCYTE; ADAPTIVE IMMUNITY; HUMAN; IMMUNOLOGY; NOTE; TH17 CELL; ZYGAPOPHYSEAL JOINT;

ADAPTIVE IMMUNITY; HUMANS; INTERLEUKIN-17; SPONDYLITIS, ANKYLOSING; TH17 CELLS; ZYGAPOPHYSEAL JOINT;

EID: 79959625184     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3351     Document Type: Editorial

References (11)

1. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J. Analysis of interleukin-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17 mediated adaptive immune response. Arthritis Res Ther 2011, 13:R95. 10.1186/ar3370, 21689402.
2. Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, Tosi I, Capon F, Trembath RC, Peris K, Nestle FO. The IL-23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011, 6:e17160. 10.1371/journal.pone.0017160, 3043090, 21364948.
3. Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA 2011, 108:9560-9565. 10.1073/pnas.1017854108, 21606346.
4. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009, 60:2633-2643. 10.1002/art.24763, 2893331, 19714651.
5. Baeten D, Sieper J, Emery P, Braun J, van der Heijde D, McInnes I, van Laar J, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Bertolino A, Wright A, Hueber W. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010, 62:2840-2841.
6. Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, McMichael A, Kollnberger S. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011, 186:2672-2680. 10.4049/jimmunol.1002653, 21248258.
7. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006, 25:309-318. 10.1016/j.immuni.2006.05.017, 16919486.
8. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB. Mast cell express IL-17A in rheumatoid arthritis synovium. J Immunol 2010, 184:3336-3340. 10.4049/jimmunol.0903566, 20200272.
9. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. Mast cell and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011,
10. Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011, 208:1127-1133. 10.1084/jem.20101712, 21576383.
11. Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M. Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology 2006, 45:1573-1575.